Search results for "OUTCOME"

showing 10 items of 5148 documents

The effect of radiofrequency catheter ablation of frequent premature ventricular complexes and arrhythmia burden on left ventricular function

2016

Background: Frequent premature ventricular complexes (PVC) are related to reversible tachycardia-induced cardiomyopathy. However, the role of arrhythmia burden on the outcome of the catheter ablation has not been fully recognised. Aim: The aim of this study was to assess the effect of catheter ablation and PVC burden in patients with and without structural heart disease (SHD) on left ventricular ejection fraction (LVEF). Methods: Transthoracic echocardiography was done before and six months after radiofrequency catheter ablation in 109 consecutive patients (61 men, age 55 ± 17 years) with frequent PVCs. Sixty-five (59.6%) patients had underlying SHD. Results: The catheter ablation procedure…

AdultMalemedicine.medical_specialtyHeart diseasemedicine.medical_treatmentCardiomyopathyCatheter ablation030204 cardiovascular system & hematologyVentricular Dysfunction Left03 medical and health sciencesQRS complex0302 clinical medicineInternal medicinemedicineHumanscardiovascular diseases030212 general & internal medicineventricular arrhythmiaAgedEjection fractionbusiness.industryleft ventricular ejection fractionStroke VolumeStroke volumeMiddle Agedmedicine.diseaseAblationstructural heart diseaseVentricular Premature ComplexesTreatment OutcomeEchocardiographyConcomitantMultivariate AnalysisCatheter Ablationcardiovascular systemCardiologyFemalepremature ventricular complexCardiology and Cardiovascular MedicinebusinessKardiologia Polska
researchProduct

Low-energy extracorporeal shock wave therapy for painful heel: a prospective controlled single-blind study.

1996

The aim of this prospective single-blind pilot study was to explore the pain-alleviating effect of low-energy extracorporeal shock wave therapy (ESWT) in painful heel associated with inferior calcaneal spurs. Thirty patients who suffered from persistent symptoms for more than 12 months qualified for low-energy ESWT and were assigned at random to two groups, real or simulated ESWT. Before beginning the treatment, any other therapy was stopped for a period of 6 weeks. The shock waves were applied by an experimental device allowing exact localization through an integrated fluoroscopy unit. Patients were treated three times at weekly intervals. Each time 1000 impulses of 0.06 mJ/mm2 were given …

AdultMalemedicine.medical_specialtyHeelExtracorporeal shock wave therapyPainPilot ProjectsLow energyLithotripsySingle-Blind StudyMedicineFluoroscopyHumansPain ManagementOrthopedics and Sports MedicineProspective StudiesFasciitisPain Measurementmedicine.diagnostic_testbusiness.industryUltrasoundGeneral MedicineMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureTreatment OutcomePatient SatisfactionOrthopedic surgeryChronic DiseaseSurgeryFemaleHeelbusinessArchives of orthopaedic and trauma surgery
researchProduct

Repetitive low-energy shock wave application without local anesthesia is more efficient than repetitive low-energy shock wave application with local …

2005

Background: It remains unclear whether application of local anesthesia (LA) interferes with clinical e!cacy of extracorporeal shock wave therapy (ESWT) for chronic plantar fasciitis. Aims: To evaluate the e"ect of local anesthesia on the clinical outcome after repetitive low-energy ESWT for chronic plantar fasciitis. Methods: Eighty-six patients with chronic plantar fasciitis were randomly assigned to receive either low-energy ESWT without LA, given weekly for three weeks (Group I, n = 45; 3 · 2000 pulses, total energy flux density per shock 0.09 mJ/mm 2 ) or identical ESWT with LA (Group II, n = 41). Primary outcome measure was: Reduction of pain from baseline to month 3 post-treatment in …

AdultMalemedicine.medical_specialtyHeelUltrasonic TherapyGroup iiPainPlantar fasciitisPilot Projectslaw.inventionLow energyRandomized controlled triallawOutcome Assessment Health CaremedicineHumansUltrasonicsOrthopedics and Sports MedicineIn patientLocal anesthesiaAnesthetics LocalFasciitisAgedbusiness.industryMiddle Agedmedicine.diseaseSurgerymedicine.anatomical_structureFasciitis PlantarAnesthesiaFemalemedicine.symptombusinessJournal of Orthopaedic Research
researchProduct

Pepsinogen testing for evaluation of the success of Helicobacter pylori eradication at 4 weeks after completion of therapy.

2014

Background and objective: Pepsinogen levels in plasma are increased by inflammation in the gastric mucosa, including inflammation resulting from Helicobacter pylori infection. A decrease in pepsinogen II level has been suggested as a reliable marker to confirm the successful eradication of infection. The aim of our study was to evaluate the potential role of pepsinogens I and II, gastrin-17 and H. pylori antibodies in confirming successful eradication. Material and methods: Altogether 42 patients (25 women, 17 men), mean age 45 years (range 23–74), were enrolled. Pepsinogens I and II, gastrin-17 and H. pylori IgG antibodies were measured in plasma samples using an ELISA test (Biohit, Oyj., …

AdultMalemedicine.medical_specialtyHelicobacter pylori infectionEfficacyGastrin-17macromolecular substancesPepsinogenGastroenterologydigestive systemHelicobacter InfectionsYoung AdultAtrophyPepsinInternal medicinePepsinogen AGastrinsmedicineGastric mucosaPepsinogen CHumansEradicationAgedMedicine(all)lcsh:R5-920biologyPlasma samplesHelicobacter pyloribusiness.industryHelicobacter pyloriMiddle Agedbiology.organism_classificationmedicine.diseaseAntibodies Bacterialdigestive system diseasesmedicine.anatomical_structureTreatment OutcomeGastric MucosaAutomotive Engineeringbiology.proteinPepsinogen IIPepsinogen; Gastrin-17; Eradication; <em>Helicobacter pylori</em>; EfficacyFemaleAntibodybusinesslcsh:Medicine (General)<em>Helicobacter pylori</em>BiomarkersMedicina (Kaunas, Lithuania)
researchProduct

Minimally invasive cerebral cavernoma surgery using keyhole approaches - solutions for technique-related limitations.

2009

Cavernomas are often small in size and located in difficultly accessible regions. Preoperative identification of the ideal surgical approach as well as the precise intraoperative implementation of the surgical plan are of critical importance for successful surgery. While aiming for minimally invasive surgical techniques and maximally effective cavernoma resection, we envisaged that employing a combination of precise and technically sophisticated virtual reality surgery planning, modern navigation systems with augmented reality features and endoscope-assisted surgical techniques should contribute to achieve this goal. Between December 2002 and November 2005, 66 patients were operated on for …

AdultMalemedicine.medical_specialtyHemangioma Cavernous Central Nervous SystemNeuronavigation610 Medicine & healthComplete resectionNeurosurgical Proceduressurgery planningResection10180 Clinic for NeurosurgeryMedicineHumansMinimally Invasive Surgical ProcedurescavernomaNeuronavigationRetrospective StudiesSurgical approachbusiness.industryBrain NeoplasmsSurgery planningEndoscopyGeneral Medicine2746 SurgerySurgery2728 Neurology (clinical)Treatment OutcomeFeature (computer vision)virtual realitySurgeryAugmented realityNeurology (clinical)businessKeyholeMinimally invasive neurosurgery : MIN
researchProduct

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C …

2008

Background and aim We assessed whether the two regimens of pegylated alpha-interferon-2b (PEG-IFN-alpha2b) plus ribavirin and pegylated alpha-interferon-2a (PEG-IFN-alpha2a) plus ribavirin showed differences in terms of sustained virological response, withdrawal due to side-effects and dose adjustment requirements in the treatment of naive chronic hepatitis C virus (HCV) patients. Methods A prospective non-randomized, open-label comparison was made of naive HCV-infected patients undergoing standard 24- or 48-week treatment with two PEG-IFN combined with weight-based dosing regimen of ribavirin (PEG-IFN-alpha2a/ribavirin, n = 91; PEG-IFN-alpha2b/ribavirin, n = 92). Results Sustained virologi…

AdultMalemedicine.medical_specialtyHepacivirusHepatitis C virusHepacivirusInterferon alpha-2medicine.disease_causeGastroenterologyAntiviral AgentsPolyethylene Glycolschemistry.chemical_compoundInterferonInternal medicineRibavirinmedicineHumansProspective StudiesProspective cohort studyHepatologymedicine.diagnostic_testbiologybusiness.industryRibavirinGastroenterologyInterferon-alphaHepatitis CHepatitis C ChronicMiddle AgedViral Loadbiology.organism_classificationmedicine.diseaseRecombinant ProteinsTreatment OutcomechemistryLiver biopsyImmunologyDrug Therapy CombinationFemalebusinessViral loadmedicine.drugJournal of gastroenterology and hepatology
researchProduct

Modified fixation free plug technique using a new 3D multilamellar implant for inguinal hernia repair: a retrospective study of a single operator cas…

2013

Aim: Implant fixation, mesh shrinkage and poor quality of tissue ingrowth are unresolved issues in modern hernia repair. Many complications reported in the literature such as bleeding, nerve entrapment, hematoma, pain, discomfort, and testicular complications, are considered to be a direct results of implant fixation. This article describes the outcomes of a procedure carried out using a handcrafted implant that addresses the issues consequent to point fixation. Methods: This was a retrospective study on the short, medium and long-term results of placing a-modified, fixation free three-dimensional polypropylene implant in 61 patients who underwent inguinal hernia repair using a novel delive…

AdultMalemedicine.medical_specialtyHerniaAdolescentmedicine.medical_treatmentprostheses and implantOperative TimeHernia InguinalPolypropylenesProsthesis DesignFixation (surgical)HematomaPostoperative ComplicationsRetrospective Studiemedicineprosthesis fixation.HumansHerniaHerniorrhaphyAgedRetrospective StudiesAged 80 and overPain Postoperativebusiness.industryHernia; Herniorrhaphy; Inguinal; Prostheses and implants; Prosthesis fixation; Adolescent; Adult; Aged; Aged 80 and over; Female; Hernia Inguinal; Herniorrhaphy; Humans; Male; Middle Aged; Operative Time; Pain Postoperative; Polypropylenes; Postoperative Complications; Prosthesis Design; Retrospective Studies; Treatment Outcome; Surgical Mesh; Surgery; Medicine (all)Medicine (all)Chronic painMiddle AgedSurgical Meshmedicine.diseaseHernia repairSurgeryInguinal herniaSettore MED/18 - Chirurgia GeneraleSurgical meshTreatment OutcomeinguinalSurgeryFemaleImplantPostoperative ComplicationbusinessProsthesis fixationPolypropylenehernia; inguinal; herniorrhaphy; prostheses and implants; prosthesis fixation.HumanHernia : the journal of hernias and abdominal wall surgery
researchProduct

Levocetirizine for the treatment of itch in psoriasis patients: An open-label pilot study in a real-world setting.

2019

Itch is the most bothersome symptom in psoriasis, often leading to impaired quality of life. Treatment of psoriasis-induced itch is frequently unsatisfactory as the various therapies employed have a delayed onset of effect. Histamine-1 receptor (H1) antihistamines are not recommended in treatment guidelines as histamine is not considered a key mediator in psoriasis. However, patients using H1 antihistamines frequently report benefits in questionnaire-based studies. To address these contradictions, we examined the short-term effects of levocetirizine, a nonsedating H1 antihistamine, on psoriasis-related itch and itch-related quality of life. In this pilot study, patients with psoriasis-relat…

AdultMalemedicine.medical_specialtyHistamine H1 Antagonists Non-SedatingTime FactorsPilot ProjectsDermatologyLevocetirizine030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineQuality of lifeimmune system diseasesPsoriasisparasitic diseasesotorhinolaryngologic diseasesMedicineEffective treatmentHumansPsoriasisskin and connective tissue diseasesH1 antihistamineDose-Response Relationship Drugbusiness.industryPruritusDelayed onsetGeneral MedicineMiddle Agedmedicine.diseaseDermatologyeye diseasesCetirizineTreatment Outcome030220 oncology & carcinogenesisConcomitantQuality of LifeFemaleOpen labelbusinessmedicine.drugDermatologic therapyREFERENCES
researchProduct

Gender-, age- and time-dependent dosing of growth hormone in adults - real-world data from a decade of clinical practice in Germany.

2017

We evaluated treatment patterns and gender-dependent dosing of growth hormone (GH) substitution in adults with GH deficiency (AGHD). Data on GH dose were collected (2003-2013) from 509 GH-treated patients (mean age: 48.9 years; 47% female) enroled in the observational German NordiWin study (NCT01543880). The impact of gender, age, treatment duration and calendar year on GH treatment patterns was evaluated by multiple regression analysis. Mean (SD) baseline GH dose (mg/day) was similar between females (0.25 [0.19] and males (0.24 [0.15]), but increased with treatment duration (at year 10, 0.55 [0.48] and 0.31 [0.09] in females and males, respectively), reflecting patient dose titration. GH d…

AdultMalemedicine.medical_specialtyHormone Replacement TherapyEndocrinology Diabetes and Metabolismmedicine.medical_treatmentPhysiology030209 endocrinology & metabolismGrowth hormoneGrowth hormone deficiency03 medical and health sciencesInsulin-like growth factor0302 clinical medicineEndocrinologySex FactorsInternal medicineGermanymedicineHumansDosingDwarfism PituitaryAgedDose-Response Relationship Drugbusiness.industryHuman Growth HormoneAge FactorsObstetrics and GynecologyMiddle Agedmedicine.diseaseClinical PracticeEndocrinologyTreatment OutcomeTransgender hormone therapy030220 oncology & carcinogenesisGh treatmentFemalebusinessReal world dataGynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology
researchProduct

The medical treatment with pasireotide in Cushing’s disease: an Italian multicentre experience based on “real-world evidence”

2019

A phase III study has demonstrated that 6-month pasireotide treatment induced disease control with good safety in 15–26% of patients with Cushing’s disease (CD). The aim of the current study was to evaluate the 6-month efficacy and safety of pasireotide treatment according to the real-world evidence. Thirty-two CD patients started pasireotide at the dose of 600 µg twice a day (bid) and with the chance of up-titration to 900 µg bid, or down-titration to 450 or 300 µg bid, on the basis of urinary cortisol (UC) levels or safety. Hormonal, clinical and metabolic parameters were measured at baseline and at 3-month and 6-month follow-up, whereas tumour size was evaluated at baseline and at 6-mont…

AdultMalemedicine.medical_specialtyHydrocortisoneEndocrinology Diabetes and MetabolismUrinary system030209 endocrinology & metabolismDiseaseSomatostatin analoguesCushing’s disease; Medical treatment; Pasireotide; Pituitary tumour; Somatostatin analoguesBody Mass IndexYoung Adult03 medical and health scienceschemistry.chemical_compound0302 clinical medicineEndocrinologyInternal medicineDiabetes mellitusHumansMedicinePituitary NeoplasmsPituitary ACTH HypersecretionAdverse effectAgedmedicine.diagnostic_testbusiness.industryPituitary tumourCushing's diseaseMiddle AgedCushing’s diseasemedicine.diseaseMagnetic Resonance ImagingPasireotidePasireotideTreatment OutcomeItalychemistry030220 oncology & carcinogenesisCushing’s disease Medical treatment Pasireotide Pituitary tumour Somatostatin analoguesFemaleOriginal ArticleWaist CircumferenceSomatostatinbusinessLipid profileBody mass indexMedical treatment
researchProduct